SCHEMBL4532941

SCHEMBL4532941

CC(C)(C)c1ccc(OC(C(=O)NO)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 4/20 0.52
ADCY6 O43306 2/20 0.52
ADCY3 O60266 2/20 0.52
ADCY9 O60503 2/20 0.52
ADCY5 O95622 2/20 0.52
ADCY8 P40145 2/20 0.52
ADCY7 P51828 2/20 0.52
ADCY2 Q08462 2/20 0.52
ADCY1 Q08828 2/20 0.52
ADCY4 Q8NFM4 2/20 0.52
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC6A9 P48067 2/20 0.46
CHRM1 P11229 1/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4531446 0.86 PPARG (0.45) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4534308 0.86 PPARG (0.50) KMT2AMEN1TDP1SLC6A9CHRM1
SCHEMBL13757732 0.85 MAPT (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2844450 0.85 HDAC7 (0.55) KMT2ACHRM1HDAC1HDAC3HDAC4
SCHEMBL13757731 0.84 KMT2A (0.50) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4538126 0.84 KLK7 (0.53) KMT2AMEN1MAPTHDAC1HDAC3
SCHEMBL4536194 0.82 HDAC1 (0.46) KMT2AMEN1CHRM1HDAC1HDAC3
SCHEMBL2844443 0.82 CYP1A2 (0.50) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4541582 0.81 HDAC4 (0.49) KMT2AMEN1MAPTHDAC1HDAC3
SCHEMBL4534419 0.81 HDAC4 (0.49) KMT2AMEN1HDAC1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 GCGR 2053/4885ADCY6 2321/4885ADCY3 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.